Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

lore these possibilities with our strategic financial advisor, RBC Capital Markets."

About Myotonic Muscular Dystrophy

Myotonic muscular dystrophy is a genetic disorder resulting in a highly variable presentation of symptoms across multiple body systems. The most prevalent symptoms include progressive muscular weakness and myotonia, cardiac arrhythmias, cognitive defects, cataracts, as well as well as endocrine, sexual, gastrointestinal and reproductive disturbances. There is currently no cure for the disease, which affects approximately 37,000 individuals in the U.S., and no specific treatment has been discovered to satisfactorily reverse or ameliorate the common symptoms associated with the disease. For more information on MMD, please visit www.mda.org.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to an additional phase II trial, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, Insmed may not apply for or receive a grant for an additional phase II trial, the FDA may interpret the results of studies differently than us, product candidates
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , 15 septembre 2014 La deuxième ... (IPAW) (semaine internationale sur la sensibilisation au ... Initiative conjointe de la Plasma Protein Therapeutics ... membres , l,IPAW vise à : ... de la collecte du plasma-aphérèse , Reconnaître ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
(Date:9/12/2014)... a magnet using an electric field (magnetoelectric memory ... the next-generation technology for information processing and storage. ... effect, due to the coexistence of electric and ... of spontaneous electric and magnetic polarizations is rare ... of the MEM effect. This article briefly reviews ...
(Date:9/12/2014)... September 12, 2014 Today, “The University” ... Indiegogo. , The film, directed by former Charlie ... Shimon Peres, Ashton Kutcher, Will.i.Am, Michio Kaku, and others. ... there’s only one university in the world devoted to ... the lives of a billion people: Singularity University. Matt ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2
... SAN DIEGO , INDIANAPOLIS , and WALTHAM, Mass. , June ... Eli Lilly and Company (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... of studies designed to test the superiority of BYDUREON™ (exenatide extended-release for injectable ... diabetes medications. , , , ...
... Inc. (Nasdaq: ISIS ) announced today that it will conduct the fourth ... Isis, development pipeline.  The last call of the series will focus on Isis, ... at 12:00 p.m. ET .  This call will be archived for a ... , , ...
... , June 15, 2010 Pieris AG,announced today the initiation ... PRS-050, an anti-VEGF Anticalin. The trial is an,open-label, dose-escalating evaluation of the ... in, Germany , the trial is underway and patients from the first ... , ...
Cached Biology Technology:DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 2DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 3DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 4DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 5DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 6DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 7DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 8DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment 9Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 2Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 3Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound 2
(Date:9/15/2014)... 2014 Schizophrenia is generally considered to be a ... factors, both genetic and environmental, with other neurodevelopmental disorders ... path for brain development is determined by the combined ... wide range of environmental factors. , However, longitudinal brain ... required in order to map the disturbances in brain ...
(Date:9/15/2014)... tip the balance between ridding the body of a ... a report appearing in The Journal of ... viruses cause chronic infections in roughly three-quarters of infected ... diseases including cirrhosis and cancer. A few patients successfully ... CD8 + T cells. The protective effects of ...
(Date:9/15/2014)... available in German . ... the fossil energy carrier natural gas offers a variety ... Nevertheless, a consequent market penetration is still pending because ... Scientists of the Helmholtz Centre for Environ-mental Research (UFZ) ... Members of the IEA Task 37 (Energy from Biogas) ...
Breaking Biology News(10 mins):Brain Development in Schizophrenia Strays from the Normal Path 2The biomethane market needs clear frame conditions for further growth 2The biomethane market needs clear frame conditions for further growth 3
... multicenter clinical trial led by a researcher at the ... will evaluate a new approach to treat triple-negative breast ... common among African-Americans and young women. The study will ... reprogram tumor cells to express a protein called an ...
... Institution (WHOI) will lead the first international, multidisciplinary assessment ... the Pacific Ocean off the Fukushima nuclear power planta ... Foundation. "This project will address fundamental ... to the ocean, and in the process enhance international ...
... can sometimes be desirable such as in the taste ... rejection that can interfere with food selection, nutrition and therapeutic ... the Monell Center and Integral Molecular describe the discovery of ... subset of bitter taste receptors. "Bitter taste is ...
Cached Biology News:New clinical trial to test novel approach to treat triple-negative breast cancer 2New clinical trial to test novel approach to treat triple-negative breast cancer 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 2Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 3Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 4Woods Hole Oceanographic Institution leads expedition to measure radioactive contaminants in Pacific 5New bitter blocker discovered 2
...
Request Info...
... vectors carry the kanamycin resistance gene that ... Spontaneous generation of multiple insertion events can ... of Geneticin Reagent. Pichia transformants are selected ... level of resistance to Geneticin Reagent. The ...
... Synthetic peptide derived from the C-terminal ... Math-2. Specificity: Specific for the ... (positive controls: human U251 A172 IMR-32 ... rat brain homogenates)Storage: Store at -20C ...
Biology Products: